| Literature DB >> 26651238 |
Jacqueline Kyungah Lim1, Yong-Seok Lee1, Annelies Wilder-Smith2, Georges Thiry3, Richard Mahoney4, In-Kyu Yoon1.
Abstract
Dengue is a public health problem in the tropics and subtropics. There are several vaccine candidates in clinical development. However, there may be gaps in the new vaccine introduction after vaccine licensure before it becomes available in developing countries. In anticipation of the first dengue vaccine candidate to be licensed, Dengue Vaccine Initiative (DVI) and, its predecessor, Pediatric Dengue Vaccine Initiative (PDVI) have been working on points for consideration to accelerate evidence-based dengue vaccine introduction, once a vaccine becomes available. In this paper, we review the history of PDVI and its successor, the DVI, and elaborate on the points of consideration for dengue vaccine introduction.Keywords: Dengue; Dengue Vaccine Initiative; introduction; points for consideration; vaccine
Mesh:
Substances:
Year: 2016 PMID: 26651238 DOI: 10.1586/14760584.2016.1129279
Source DB: PubMed Journal: Expert Rev Vaccines ISSN: 1476-0584 Impact factor: 5.217